Science Saturday: Uterine microbe found to have disease-causing behavior in endometrial cancer
A tiny microbe thriving in the uterine microbiome — a population of bacteria, viruses, yeasts/fungi in and around the uterus— could be a contributing driver of endometrial cancer, according to a new Mayo Clinic study.  "We have found that a microbe that is particularly associated with endometrial cancer is capable of pathogenic behavior, and is stimulated by one of the main risk factors for the disease — estrogen exposure," explains Marina Walther-Antonio, Ph.D.,  a researcher within the Mayo… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 4, 2021 Category: Databases & Libraries Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Investor Update - August 18, 2021 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Media News - August 18, 2021 Category: Pharmaceuticals Source Type: news

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma
- Oncology - Cancer (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 27, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Current criteria for noninvasive transvaginal ultrasound used to determine the need for endometrial biopsy not as accurate in Black women (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 23, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Radiology, Journal, Source Type: news

Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
FRIDAY, July 23, 2021 -- Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2021 Category: Pharmaceuticals Source Type: news

FDA Fully Approves Combination for Advanced Endometrial Cancer FDA Fully Approves Combination for Advanced Endometrial Cancer
Pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma is now fully approved.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma
- Oncology - Cancer (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
KENILWORTH& WOODCLIFF, N.J.--(BUSINESS WIRE) July 22, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 22, 2021 Category: Drugs & Pharmacology Source Type: news

Screening Often Misses Endometrial Cancer in Black Women
TUESDAY, July 20, 2021 -- A noninvasive method of screening for endometrial cancer often fails to detect signs of it in Black women, a new study says. The findings raise questions about the use of transvaginal ultrasound (TVUS) to determine the need... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2021 Category: General Medicine Source Type: news

Ultrasound misses endometrial cancer in Black women
Using transvaginal ultrasound to measure endometrial thickness to determin...Read more on AuntMinnie.comRelated Reading: Radiologists can help reduce disparities around COVID-19 6 ways to address healthcare inequality in radiology Hysterosalpingo contrast ultrasound shows promise in infertility exams Ultrasound steps up in COVID-19 pandemic Model predicts metastases in endometrial cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 15, 2021 Category: Radiology Source Type: news

Screening often misses endometrial cancer in Black women
In this study using a simulated cohort, TVUS endometrial thickness screening missed over four times more cases of endometrial cancer among Black women versus White women owing to the greater prevalence of fibroids and non-endometrioid histology type that occurs among Black women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

Racial Disparities Persist in Endometrial Cancer Care Racial Disparities Persist in Endometrial Cancer Care
Women who were Black, Latina, American Indian, or Alaska Native were less likely than White women to receive guidelines-adherent treatment for endometrial cancer, a study shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 1, 2021 Category: Cancer & Oncology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Lenvatinib + pembrolizumab is not cost effective for recurrent MSS endometrial cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Lower BMI Cutoff Tied to Endometrial Cancer in Chinese Women
Lower obesity threshold of BMI ≥25 kg/m2 tied to increased risk of endometrial cancer in Asian women presenting with postmenopausal bleeding (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 30, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news

Lower BMI Cutoff Tied to Endometrial Cancer in Chinese Women
WEDNESDAY, June 30, 2021 -- Body mass index (BMI) ≥25 kg/m2 is independently associated with increased risk of endometrial cancer among Chinese women presenting with postmenopausal bleeding, according to a study published online June 30 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2021 Category: Pharmaceuticals Source Type: news

Postmenopausal bleeding may be a sign of endometrial cancer in obese Asian women
(The North American Menopause Society (NAMS)) The link between obesity and the risk of endometrial cancer has been well documented. A new study, however, shows that an even lower body mass index (BMI) than previously thought can signal an increased risk in Asian women with postmenopausal bleeding. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 30, 2021 Category: International Medicine & Public Health Source Type: news

Consumer Health: Treating polycystic ovary syndrome
Polycystic ovary syndrome is a hormonal disorder common among women of reproductive age. Complications can include infertility, gestational diabetes or pregnancy-induced high blood pressure, miscarriage or premature birth, and endometrial cancer. Signs and symptoms of polycystic ovary syndrome vary. A diagnosis is made when women experience at least two of these signs: Irregular periods.Elevated levels of male [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 11, 2021 Category: Databases & Libraries Source Type: news

Pembrolizumab in dMMR/MSI-H unresectable or metastatic endometrial cancer: substantial gain in life-years at acceptable cost in the US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2021 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - April 2021
GSK’s Checkpoint Inhibitor Jemperli Gains Approval for Endometrial Cancer The FDA has given accelerated approval to GSK’s Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody used to treat adults with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 30, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Immunotherapy for dMMR Endometrial Cancer
Jemperli approved for dMMR endometrial cancer that progressed after platinum - containing chemotherapy treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 24, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Immunotherapy for dMMR Endometrial Cancer
FRIDAY, April 23, 2021 -- The anti-programmed death receptor 1 (PD-1) monotherapy Jemperli (dostarlimab) received approval for treatment of mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves New Immunotherapy for Endometrial Cancer FDA Approves New Immunotherapy for Endometrial Cancer
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair (dMMR).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Media News)
Source: Roche Media News - April 23, 2021 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Jemperli (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer
London UK 22 April 2021 -- GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company’s Biologics... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 22, 2021 Category: Drugs & Pharmacology Source Type: news

FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study reveals the 3D structure of human uterine endometrium and adenomyosis tissue
(Niigata University) Recent advances in tissue-clearing-based 3D imaging have permitted researchers to establish a new baseline 3D structure of the endometrial glands, including the formation of a rhizome network in the stratum basalis that expands horizontally along the muscular layer. These findings have implications in understanding the mechanisms underlying normal endometrial tissue processes such as menstruation and fertilized egg implantation, and in clarifying the pathogenesis of endometrium-related diseases, notably adenomyosis, endometriosis, and endometrial cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2021 Category: International Medicine & Public Health Source Type: news

An international study reveals how the 'guardian' of the genome works
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * Teams from the CNIO, the Leiden University Medical Center and the Netherlands Cancer Institute use electron cryo-electron microscopy to explain how the MutS protein, considered the 'guardian' of the genome, manages to repair the errors that can occur in DNA during cell division* An in-depth understanding of this process is essential to understand how mutations occur that can lead to the development of certain types of tumour, such as Lynch syndrome and endometrial cancer (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 6, 2021 Category: Cancer & Oncology Source Type: news

An IUD Could Ward Off Endometrial Cancer in Women at Risk
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 26, 2021 Category: Cancer & Oncology Tags: Oncology, Obstetrics, News, Source Type: news

An IUD Could Ward Off Endometrial Cancer in Women at Risk
FRIDAY, March 26, 2021 -- For some patients who have early endometrial cancer or a precancerous condition, a hysterectomy may not be a good option because of serious health issues or the desire to preserve fertility. Now, a new Australian study has... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 26, 2021 Category: General Medicine Source Type: news

An IUD Could Ward Off Endometrial Cancer in Women at Risk
Title: An IUD Could Ward Off Endometrial Cancer in Women at RiskCategory: Health NewsCreated: 3/26/2021 12:00:00 AMLast Editorial Review: 3/26/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 26, 2021 Category: Cancer & Oncology Source Type: news

Endometrial cancer: Patient reduced her thickened endometrial lining naturally
ENDOMETRIAL cancer begins in the uterus - part of the female reproductive system - which the NHS regards as "common", as there are over 9,400 cases each year in the UK. Do you know the warning signs? (Source: Daily Express - Health)
Source: Daily Express - Health - March 21, 2021 Category: Consumer Health News Source Type: news

Estrogen receptor tied to outcomes in DCIS
The estrogen receptor plays a key role in predicting long-term outcomes in patient...Read more on AuntMinnie.comRelated Reading: SNMMI confirms Medicare reimbursement error for Cerianna PET aids in treatment of metastatic breast cancer patients SNMMI, Zionexa call out CMS for reimbursement error Black women die more frequently from breast cancer AI tool beats traditional breast cancer risk assessments FES-PET could predict endometrial cancer outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 16, 2021 Category: Radiology Source Type: news

EU Green Light for Dostarlimab in Some Endometrial Cancers EU Green Light for Dostarlimab in Some Endometrial Cancers
A new PD-1 antagonist, dostarlimab, has been recommended for approval for use in some women with advanced/recurrent endometrial cancer.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Sentinel lymph node mapping best approach to guide adjuvant therapy in endometrial cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

Study shows new treatment pathway to prevent and treat endometrial cancer recurrence
(Yale University) In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2021 Category: Cancer & Oncology Source Type: news

Oral Contraceptives May Reduce Cancer Risk
Oral Contraceptives May Reduce Ovarian and Endometrial Cancer Risk (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 5, 2021 Category: General Medicine Source Type: news

Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 4, 2021 Category: Internal Medicine Tags: Hematology-Oncology News Source Type: news

EIT Health invests €3M in innovations for endometrial cancer and Parkinson's disease
The Wild Card open innovation programme has selected  two innovator teams from Spain and Germany. (Source: mobihealthnews)
Source: mobihealthnews - February 1, 2021 Category: Information Technology Source Type: news

New, simplified genetic test effectively screens for hereditary cancers
(Elsevier) Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of DNA in colon, endometrial, and other cancers. This alternative to complex, multi-step testing workflows can also determine causes of MMR deficiency often missed by current clinical tests. Their results are presented in The Journal of Molecular Diagnostics, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Oral Contraceptives Tied to Lower Risk for Certain Cancers
The drugs may increase the risk of breast cancer, but may lower the risk of ovarian and endometrial cancers. (Source: NYT Health)
Source: NYT Health - January 5, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Ovarian Cancer Breast Cancer Women and Girls Deaths (Fatalities) Birth Control and Family Planning Source Type: news

Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
MONDAY, Dec. 21, 2020 -- Oral contraceptives have a lasting protective effect against ovarian and endometrial cancer, according to a study published online Dec. 17 in Cancer Research. Torgny Karlsson, Ph.D., from Uppsala University in Sweden, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

Oral contraceptive pills protect against ovarian and endometrial cancer
(Uppsala University) A comprehensive study from Uppsala University, involving more than 250,000 women, shows that oral contraceptive use protects against ovarian and endometrial cancer. The protective effect remains for several decades after discontinuing the use. The study is published in the journal Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

Two-Drug Combo Standard of Care in Advanced Endometrial Cancer Two-Drug Combo Standard of Care in Advanced Endometrial Cancer
Survival outcomes for the combination paclitaxel-carboplatin were similar to those with paclitaxel, doxorubicin, and cisplatin but with lower toxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FES-PET could predict endometrial cancer outcomes
PET imaging with the radiotracer F-18 fluoroestradiol (FES) can help determine...Read more on AuntMinnie.comRelated Reading: Imaging agent for breast cancer PET gets FDA nod FES-PET enhances treatment for metastatic breast cancer FES-PET detects estrogen-receptor-positive breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 7, 2020 Category: Radiology Source Type: news

Constitutive expression of progesterone receptor isoforms promotes the development of hormone-dependent ovarian neoplasms
Differences in the relative abundances of the progesterone receptor (PGR) isoforms PGRA and PGRB are often observed in women with reproductive tract cancers. To assess the importance of the PGR isoform ratio in the maintenance of the reproductive tract, we generated mice that overexpress PGRA or PGRB in all PGR-positive tissues. Whereas few PGRA-overexpressing mice developed reproductive tract tumors, all PGRB-overexpressing mice developed ovarian neoplasms that were derived from ovarian luteal cells. Transcriptomic analyses of the ovarian tumors from PGRB-overexpressing mice revealed enhanced AKT signaling and a gene expr...
Source: Signal Transduction Knowledge Environment - October 5, 2020 Category: Science Authors: Wetendorf, M., Li, R., Wu, S.-P., Liu, J., Creighton, C. J., Wang, T., Janardhan, K. S., Willson, C. J., Lanz, R. B., Murphy, B. D., Lydon, J. P., DeMayo, F. J. Tags: STKE Research Articles Source Type: news

Mayo Clinic Q and A: Understanding endometrial cancer
DEAR MAYO CLINIC: My 54-year-old sister was diagnosed recently with early-stage endometrial cancer. She only went to the doctor because she had bleeding between menstrual cycles. I'm wondering if I am at risk, too, and if there is anything I can do to reduce my risk. Is there a screening test? ANSWER: An increased risk for endometrial [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 29, 2020 Category: Databases & Libraries Source Type: news